A ranar 27 ga Yuli, 2023, Lilly ta ba da sanarwar cewa binciken Mount-3 na Tirzepatide don kula da marasa lafiya masu kiba da kuma binciken Dutsen-4 don kula da asarar marasa lafiya masu kiba ya kai matakin ƙarshe na farko da maɓallin ƙarshen sakandare.Wannan shine bincike na uku da na huɗu na nasara na kashi III wanda Tirzepatide ya samu bayan Dutsen-1 da Dutsen-2.
SURMOUNT-3 (NCT04657016) babban ci gaba ne, bazuwar, makafi biyu, daidaici, gwajin sarrafa wuribo wanda ke yin rajistar jimlar mahalarta 806 da aka tsara don nuna fifikon Tirzepatide akan placebo dangane da canjin kashi a canjin nauyi bayan bazuwar da adadin adadin mahalarta waɗanda suka rasa ≥5% bayan bazuwar a makonni 72.
Sakamakon binciken SURMOUNT-3 ya nuna cewa Tirzepatide ya sadu da duk matakan ƙarshe, wato, bayan makonni 72 na maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin maganin . ya sami asarar nauyi fiye da kashi 5%.Bayanan asibiti na musamman sun nuna cewa marasa lafiya da aka bi da su tare da Tirzepatide sun rasa matsakaicin 21.1% na nauyin jiki idan aka kwatanta da placebo;Haɗe tare da lokacin sa baki na makonni 12, marasa lafiya da aka yi wa magani tare da Tirzepatide sun rasa matsakaicin kashi 26.6 na nauyin jikinsu.Bugu da ƙari, 94.4% na marasa lafiya sun rasa ≥5% na nauyin su a cikin ƙungiyar Tirzepatide, idan aka kwatanta da 10.7% a cikin rukunin placebo.
SURMOUNT-4 (NCT04660643) ne mai multicenter, bazuwar, makafi biyu, a layi daya, gwajin sarrafa wuribo wanda ke yin rajistar jimlar mahalarta 783 da aka tsara don nuna cewa Tirzepatide ya fi placebo a cikin canjin nauyi a cikin bazuwar 88-mako.
Sakamakon ya nuna cewa bayan makonni biyu na makafi na 37 ~ 88 makonni, marasa lafiya a cikin ƙungiyar Tirzepatide sun rasa nauyi fiye da a cikin rukunin placebo.Dangane da aminci, ba binciken SURMOUNT-3 ko SURMOUNT-4 ba ya lura da sabbin siginonin aminci.
Tun lokacin da Novo Nordisk's blockbuster rage cin abinci magani Semaglutide, haɗe tare da m yarda da Musk, ya zama ban mamaki Internet shahararriyar samfurin da kuma na yanzu nauyi asara sarki.Buƙatar kasuwar asarar nauyi tana da girma, kuma akwai magunguna biyu na GLP-1 a halin yanzu akan kasuwa, Liraglutide da Semaglutide, amma Liraglutide shiri ne na ɗan gajeren aiki, wanda ba zai iya yin gasa tare da shirye-shiryen dogon aiki dangane da bin haƙuri. , kuma duniyar asarar nauyi na yanzu na ɗan lokaci na Semaglutide ne.
Har ila yau, sarkin filin GLP-1, Lilly yana sha'awar teku mai launin shuɗi na kasuwar asarar nauyi - don haka Lilly ta ƙaddamar da kalubale da farko a kan Tirzepatide don kwace wuri a cikin kasuwar asarar nauyi.
Tirzepatide shine GIPR/GLP-1R dual agonist na mako-mako, GIP (glucose-dogara insulin stimulating polypeptide) wani memba ne na dangin glucagon peptide, tare da tasirin haɓaka siginin insulin ta hanyar dogaro da insulin da kuma haɓaka ƙwayar glucagon a cikin hypoglycemic. Jiha, GIPR/GLP-1R dual agonist na iya samar da sarrafa sukari na jini, asarar nauyi da sauran tasirin ta hanyar ƙarfafa duka GIP da GLP-1 hanyoyin ƙasa.FDA ta amince da Tirzepatide a cikin 2022-5 (sunan kasuwanci: Mounjaro) don amfani a hade tare da abinci da motsa jiki don inganta sarrafa glycemic a cikin manya masu fama da ciwon sukari na 2.
Lokacin aikawa: Satumba 18-2023